Dual mTORC1/2 inhibition in a preclinical xenograft tumor model of endometrial cancer

Gynecologic Oncology

Volumn 132, Issue 2, 2014, Pages 468-473

  Korets, Sharmilee Bansal ^a   Musa, Fernanda ^a   Curtin, John ^a,b   Blank, Stephanie V ^a,b   Schneider, Robert J ^b  

^a NEW YORK UNIVERSITY MEDICAL CENTER   (United States)

^b NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Akt; eIF4E; Endometrial cancer; mTOR pathway; Preclinical study; Rapamycin; therapeutics; Translational regulation

Indexed keywords

AKT; EIF4E; ENDOMETRIAL CANCER; MTOR PATHWAY; PRECLINICAL STUDY; RAPAMYCIN; THERAPEUTICS; TRANSLATIONAL REGULATION;

ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; CARCINOMA, ENDOMETRIOID; CELL GROWTH PROCESSES; CELL LINE, TUMOR; ENDOMETRIAL NEOPLASMS; FEMALE; INDOLES; MICE; MICE, INBRED BALB C; MICE, NUDE; MULTIPROTEIN COMPLEXES; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS C-AKT; PURINES; RANDOM ALLOCATION; SIGNAL TRANSDUCTION; SIROLIMUS; TOR SERINE-THREONINE KINASES; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84894065692     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2013.11.027     Document Type: Article

References (32)

1. Figures Cancer Facts 2013 Atlanta: American Cancer Society 2013
2. J.I. Sorosky Endometrial cancer Obstet Gynecol 111 2008 436 447
3. H.B. Salvesen, I.S. Haldorsen, and J. Trovik Markers for individualised therapy in endometrial carcinoma Lancet Oncol 13 2012 e353 e361
4. J.L. Hecht, and G.L. Mutter Molecular and pathologic aspects of endometrial carcinogenesis J Clin Oncol 24 2006 4783 4791
5. S.B. Korets, S. Czok, S.V. Blank, J.P. Curtin, and R.J. Schneider Targeting the mTOR/4E-BP pathway in endometrial cancer Clin Cancer Res 17 2011 7518 7528
6. N. Bansal, V. Yendluri, and R.M. Wenham The molecular biology of endometrial cancers and the implications for pathogenesis, classification, and targeted therapies Cancer Control 16 2009 8 13
7. C.H. Choi, J.S. Lee, S.R. Kim, T.J. Kim, J.W. Lee, and B.G. Kim et al. Clinical significance of pmTOR expression in endometrioid endometrial carcinoma Eur J Obstet Gynecol Reprod Biol 153 2010 207 210
8. A. Torres, K. Torres, A. Pesci, M. Ceccaroni, T. Paszkowski, and P. Cassandrini et al. Deregulation of miR-100, miR-99a and miR-199b in tissues and plasma coexists with increased expression of mTOR kinase in endometrioid endometrial carcinoma BMC Cancer 12 2012 369
9. V.L. Bae-Jump, C. Zhou, J.F. Boggess, Y.E. Whang, L. Barroilhet, and P.A. Gehrig Rapamycin inhibits cell proliferation in type I and type II endometrial carcinomas: a search for biomarkers of sensitivity to treatment Gynecol Oncol 119 2010 579 585
10. D. Silvera, S.C. Formenti, and R.J. Schneider Translational control in cancer Nat Rev Cancer 10 2010 254 266
11. D.M. Sabatini mTOR and cancer: insights into a complex relationship Nat Rev Cancer 6 2006 729 734
12. V.L. Bae-Jump, C. Zhou, J.F. Boggess, and P.A. Gehrig Synergistic effect of rapamycin and cisplatin in endometrial cancer cells Cancer 115 2009 3887 3896
13. A. Shafer, C. Zhou, P.A. Gehrig, J.F. Boggess, and V.L. Bae-Jump Rapamycin potentiates the effects of paclitaxel in endometrial cancer cells through inhibition of cell proliferation and induction of apoptosis Int J Cancer 126 2010 1144 1154
14. A. Carracedo, L. Ma, J. Teruya-Feldstein, F. Rojo, L. Salmena, and A. Alimonti et al. Inhibition of mTORC1 leads to MAPK pathway activation through a PI3K-dependent feedback loop in human cancer J Clin Invest 118 2008 3065 3074
15. K.E. O'Reilly, F. Rojo, Q.B. She, D. Solit, G.B. Mills, and D. Smith et al. mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt Cancer Res 66 2006 1500 1508
16. K.H. Lu, W. Wu, B. Dave, B.M. Slomovitz, T.W. Burke, and M.F. Munsell et al. Loss of tuberous sclerosis complex-2 function and activation of mammalian target of rapamycin signaling in endometrial carcinoma Clin Cancer Res 14 2008 2543 2550
17. D. Silvera, R. Arju, F. Darvishian, P.H. Levine, L. Zolfaghari, and J. Goldberg et al. Essential role for eIF4GI overexpression in the pathogenesis of inflammatory breast cancer Nat Cell Biol 11 2009 903 908
18. S.A. Kang, M.E. Pacold, C.L. Cervantes, D. Lim, H.J. Lou, and K. Ottina et al. mTORC1 phosphorylation sites encode their sensitivity to starvation and rapamycin Science 341 2013 1236566
19. L. Catasus, A. Gallardo, M. Cuatrecasas, and J. Prat Concomitant PI3K-AKT and p53 alterations in endometrial carcinomas are associated with poor prognosis Mod Pathol 22 2009 522 529
20. L. Catasus, A. Gallardo, M. Cuatrecasas, and J. Prat PIK3CA mutations in the kinase domain (exon 20) of uterine endometrial adenocarcinomas are associated with adverse prognostic parameters Mod Pathol 21 2008 131 139
21. K.J. Dedes, D. Wetterskog, A. Ashworth, S.B. Kaye, and J.S. Reis-Filho Emerging therapeutic targets in endometrial cancer Nat Rev Clin Oncol 8 2011 261 271
22. S. Darb-Esfahani, A. Faggad, A. Noske, W. Weichert, A.C. Buckendahl, and B. Muller et al. Phospho-mTOR and phospho-4EBP1 in endometrial adenocarcinoma: association with stage and grade in vivo and link with response to rapamycin treatment in vitro J Cancer Res Clin Oncol 135 2009 933 941
23. K.H. Lu, W. Wu, B. Dave, B.M. Slomovitz, T.W. Burke, and M.F. Munsell et al. Loss of tuberous sclerosis complex-2 function and activation of mammalian target of rapamycin signaling in endometrial carcinoma Clin Cancer Res 14 2008 2543 2550
24. H. Wahl, S. Daudi, M. Kshirsagar, K. Griffith, L. Tan, and J. Rhode et al. Expression of metabolically targeted biomarkers in endometrial carcinoma Gynecol Oncol 116 2010 21 27
25. A.M. Oza, L. Elit, M.S. Tsao, S. Kamel-Reid, J. Biagi, and D.M. Provencher et al. Phase II study of temsirolimus in women with recurrent or metastatic endometrial cancer: a trial of the NCIC Clinical Trials Group J Clin Oncol 29 2011 3278 3285
26. I. Ray-Coquard, L. Favier, B. Weber, C. Roemer-Becuwe, P. Bougnoux, and M. Fabbro et al. Everolimus as second- or third-line treatment of advanced endometrial cancer: ENDORAD, a phase II trial of GINECO Br J Cancer 108 2013 1771 1777
27. B.M. Slomovitz, K.H. Lu, T. Johnston, R.L. Coleman, M. Munsell, and R.R. Broaddus et al. A phase 2 study of the oral mammalian target of rapamycin inhibitor, everolimus, in patients with recurrent endometrial carcinoma Cancer 116 2010 5415 5419
28. N. Columbo, S. MMeekin, P. Schwartz, J. Kostka, C. Sessa, and P. Gehig et al. A phase II trial of the mTOR inhibitor AP23573 as a single agent in advanced endometrial cancer J Clin Oncol l 25 2007 [Abstr. 5516]
29. G.F. Fleming, V.L. Filiaci, P. Hanjani, J.J. Burke II, S.A. Davidson, and K.K. Leslie et al. Hormonal therapy plus temsirolimus for endometrial carcinoma (EC): gynecological Group Trial J Clin Oncol 2011 29
30. A.M. Oza, A. Poveda, A.R. Clamp, S. Pignata, G. Scambia, and J.M. Del Campo et al. A randomized phase II (RP2) trial of ridaforolimus (R) compared with progestin (P) or chemotherapy (P) in female adult patients with advanced endometrial carcinoma J Clin Oncol 29 2011 [Abstr. 5009]
31. H.J. Mackay, S. Welch, M.S. Tsao, J.J. Biagi, L. Elit, and P. Ghatage et al. Phase II study of oral ridaforolimus in patients with metastatic and/or locally advanced recurrent endometrial cancer J Clin Oncol 29 2011 [Abstr. 5013]
32. N. Cybulski, and M.N. Hall TOR complex 2: a signaling pathway of its own Trends Biochem Sci 34 2009 620 627